Cobimetinib
- Generic Name
- Cobimetinib
- Brand Names
- Cotellic
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21F3IN3O2
- CAS Number
- 934660-93-2
- Unique Ingredient Identifier
- ER29L26N1X
- Background
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metasta...
- Indication
Cobimetinib is indicated in combination with vemurafenib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. As a single agent, cobimetinib is also indicated for the treatment of adult patients with histiocytic neoplasms.
- Associated Conditions
- Histiocytic Neoplasm, Metastatic Melanoma, Unresectable Melanoma
- Associated Therapies
- -
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1163
- Registration Number
- NCT01928394
- Locations
- πΊπΈ
Local Institution - 0001, Atlanta, Georgia, United States
πΊπΈLocal Institution - 0007, Portland, Oregon, United States
πΊπΈLocal Institution - 0002, Nashville, Tennessee, United States
The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 5
- Registration Number
- NCT01813214
- Locations
- πΊπΈ
Georgetown Lombardi Comprehsnive Cancer Center, Washington, District of Columbia, United States
πΊπΈUniversity of Virginia Health System, Charlottesville, Virginia, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 495
- Registration Number
- NCT01689519
- Locations
- π§πͺ
UZ Antwerpen, Edegem, Belgium
π¬π§Velindre Cancer Centre, Cardiff, United Kingdom
π¦πΊLismore Base Hospital; Cancer Care & Haematology Unit, Lismore, New South Wales, Australia
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT01656642
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
πΊπΈUCLA, Los Angeles, California, United States
πΊπΈThe Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT01562275
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2017-10-24
- Target Recruit Count
- 10
- Registration Number
- NCT01495988
- Locations
- πΊπΈ
Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States
πΊπΈThe Angeles Clinic, Los Angeles, California, United States
πΊπΈGeorgetown Lombardi Comprehensive Cancer Center, Washington, D.C., District of Columbia, United States
A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy Participants
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01277718
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 131
- Registration Number
- NCT01271803
- Locations
- πΊπΈ
The Angeles Clinic and Research Institute, Santa Monica Office, Santa Monica, California, United States
πΊπΈUCLA Department of Medicine, Los Angeles, California, United States
πΊπΈUniversity of California at San Francisco, San Francisco, California, United States
A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants
- First Posted Date
- 2010-11-29
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01249131
Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2016-12-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT00996892
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.